Walleye Capital LLC Invests $1.57 Million in Korro Bio, Inc. (NASDAQ:KRRO)

Walleye Capital LLC acquired a new stake in Korro Bio, Inc. (NASDAQ:KRRO - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 41,228 shares of the company's stock, valued at approximately $1,570,000. Walleye Capital LLC owned 0.44% of Korro Bio as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS acquired a new stake in shares of Korro Bio during the 4th quarter valued at approximately $53,000. AlphaQuest LLC increased its stake in Korro Bio by 23.2% in the 4th quarter. AlphaQuest LLC now owns 2,189 shares of the company's stock valued at $83,000 after purchasing an additional 412 shares in the last quarter. Wells Fargo & Company MN raised its holdings in Korro Bio by 32.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,392 shares of the company's stock worth $129,000 after purchasing an additional 831 shares during the last quarter. Legal & General Group Plc boosted its position in Korro Bio by 664.1% during the fourth quarter. Legal & General Group Plc now owns 4,325 shares of the company's stock worth $165,000 after purchasing an additional 3,759 shares in the last quarter. Finally, Trexquant Investment LP acquired a new stake in Korro Bio in the fourth quarter valued at $211,000. Hedge funds and other institutional investors own 13.18% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on KRRO. Oppenheimer began coverage on shares of Korro Bio in a research report on Friday, January 10th. They issued an "outperform" rating and a $155.00 price objective on the stock. Royal Bank of Canada reduced their price target on shares of Korro Bio from $105.00 to $95.00 and set an "outperform" rating on the stock in a report on Wednesday, March 19th. Chardan Capital initiated coverage on shares of Korro Bio in a research note on Wednesday, April 16th. They set a "buy" rating and a $25.00 price objective for the company. Finally, HC Wainwright reissued a "buy" rating and set a $115.00 price objective on shares of Korro Bio in a research note on Thursday, March 20th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $120.43.

Korro Bio Price Performance

KRRO stock traded up $0.20 during trading on Friday, reaching $17.64. 19,392 shares of the stock traded hands, compared to its average volume of 94,747. The firm has a market capitalization of $165.62 million, a PE ratio of -1.87 and a beta of 2.31. The business's 50 day moving average price is $19.77 and its 200-day moving average price is $37.45. Korro Bio, Inc. has a 52-week low of $11.13 and a 52-week high of $98.00.

Korro Bio (NASDAQ:KRRO - Get Free Report) last posted its earnings results on Tuesday, March 18th. The company reported ($2.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.33) by $0.07. The business had revenue of $2.27 million for the quarter. On average, equities research analysts predict that Korro Bio, Inc. will post -9.52 earnings per share for the current year.

Korro Bio Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).